Korean J Physiol Pharmacol.  2025 Mar;29(2):227-233. 10.4196/kjpp.24.239.

The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer’s disease

• Kim TE
• Bae J
• Hong S
• Jeon HJ
• Moon Y

• KMID: 2565434
• DOI: http://doi.org/10.4196/kjpp.24.239

Abstract

Donepezil, an acetylcholinesterase inhibitor, is widely used for managing the symptoms of Alzheimer’s disease (AD), yet its clinical response varies widely among individuals. This study aims to investigate the influence of CYP2D6 genetic variants on donepezil concentration, treatment response, and adverse effects in Korean patients with AD dementia. We conducted a longitudinal study involving 76 patients receiving either 5 mg or 10 mg of donepezil. Genetic testing identified 9 CYP2D6 alleles, categorizing patients by metabolizing abilities. Blood sampling for plasma concentrations of donepezil were performed at steady-state. Mini-Mental State Examination (MMSE) were conducted at 12, 24 and 36 months after the initiation of treatment. Adverse events were collected throughout the study period. Donepezil plasma concentrations differed significantly among metabolizer statuses (mean 56.8 ± 27.1 ng/ml in normal metabolizers vs. 69.6 ± 30.1 ng/ml in intermediate metabolizers, p = 0.042), but these differences did not affect cognitive function over three years as assessed by MMSE. Additionally, there was no significant correlation between donepezil plasma concentration and adverse events. Our study is the first to elucidate the associations between CYP2D6 genotype and the concentration, clinical response or adverse events of donepezil in Korean patients with AD dementia. Larger studies are necessary to fully understand the impact of CYP2D6 genetic variants on therapeutic outcomes with donepezil.

Keyword

Alzheimer disease; Cognition; Cytochrome P-450 CYP2D6; Donepezil

Figure

• 

  Fig. 1 Donepezil plasma concentrations according to CYP2D6 metabolizer status. IM, intermediate metabolizer; NM, normal metabolizer.

Reference

1. World Health Organization. 2021. Global status report on the public health response to dementia. World Health Organization. Available from: https://www.who.int/publications/i/item/9789240033245. cited 2024 July 1.

2. 2023; 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 19:1598–1695. DOI: 10.1002/alz.13016. PMID: 36918389.

3. Kocahan S, Doğan Z. 2017; Mechanisms of Alzheimer's disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, Tau protein and other risk factors. Clin Psychopharmacol Neurosci. 15:1–8. DOI: 10.9758/cpn.2017.15.1.1. PMID: 28138104. PMCID: PMC5290713.

4. McGleenon BM, Dynan KB, Passmore AP. 1999; Acetylcholinesterase inhibitors in Alzheimer's disease. Br J Clin Pharmacol. 48:471–480. DOI: 10.1046/j.1365-2125.1999.00026.x. PMID: 10583015. PMCID: PMC2014378.

5. Cacabelos R. 2008; Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci. 258 Suppl 1:28–47. DOI: 10.1007/s00406-007-1006-x. PMID: 18344047.

6. Chamnanphon M, Wainipitapong S, Wiwattarangkul T, Chuchuen P, Nissaipan K, Phaisal W, Tangwongchai S, Sukasem C, Wittayalertpanya S, Gaedigk A, Aniwattanapong D, Chariyavilaskul P. 2020; CYP2D6 predicts plasma donepezil concentrations in a cohort of Thai patients with mild to moderate dementia. Pharmgenomics Pers Med. 13:543–551. DOI: 10.2147/PGPM.S276230. PMID: 33177862. PMCID: PMC7649971.

7. Kagawa Y, Yamamoto Y, Ueno A, Maeda T, Obi T. 2021; Impact of CYP2D6, CYP3A5, and ABCB1 polymorphisms on plasma concentrations of donepezil and its metabolite in patients with Alzheimer disease. Ther Drug Monit. 43:429–435. DOI: 10.1097/FTD.0000000000000823. PMID: 33065613.

8. Varsaldi F, Miglio G, Scordo MG, Dahl ML, Villa LM, Biolcati A, Lombardi G. 2006; Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol. 62:721–726. DOI: 10.1007/s00228-006-0168-1. PMID: 16845507.

9. Heo HJ, Park SY, Lee YS, Shin HK, Hong KW, Kim CD. 2020; Combination therapy with cilostazol, aripiprazole, and donepezil protects neuronal cells from β-amyloid neurotoxicity through synergistically enhanced SIRT1 expression. Korean J Physiol Pharmacol. 24:299–310. DOI: 10.4196/kjpp.2020.24.4.299. PMID: 32587124. PMCID: PMC7317180.

10. Kumar A, Gupta V, Sharma S. 2024. Donepezil [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513257/. cited 2024 July 8.

11. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. 1996; PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics. 6:351–355. DOI: 10.1097/00008571-199608000-00008. PMID: 8873221.

12. Lundqvist E, Johansson I, Ingelman-Sundberg M. 1999; Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 226:327–338. DOI: 10.1016/S0378-1119(98)00567-8. PMID: 9931507.

13. Nofziger C, Turner AJ, Sangkuhl K, Whirl-Carrillo M, Agúndez JAG, Black JL, Dunnenberger HM, Ruano G, Kennedy MA, Phillips MS, Hachad H, Klein TE, Gaedigk A. 2020; PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 107:154–170. DOI: 10.1002/cpt.1643. PMID: 31544239. PMCID: PMC6925641.

14. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV, Hoffman JM. 2017; Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 19:215–223. DOI: 10.1038/gim.2016.87. PMID: 27441996. PMCID: PMC5253119.

15. Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ. 2018; CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res. 41:921–930. DOI: 10.1007/s12272-018-1075-6. PMID: 30191460.

16. Subramaniapillai S, Almey A, Natasha Rajah M, Einstein G. 2021; Sex and gender differences in cognitive and brain reserve: implications for Alzheimer's disease in women. Front Neuroendocrinol. 60:100879. DOI: 10.1016/j.yfrne.2020.100879. PMID: 33137359.

17. Scarmeas N, Albert SM, Manly JJ, Stern Y. 2006; Education and rates of cognitive decline in incident Alzheimer's disease. J Neurol Neurosurg Psychiatry. 77:308–316. DOI: 10.1136/jnnp.2005.072306. PMID: 16484637. PMCID: PMC2077720.

18. Yaowaluk T, Senanarong V, Limwongse C, Boonprasert R, Kijsanayotin P. 2019; Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer's disease and vascular dementia. Pharmgenomics Pers Med. 12:209–224. DOI: 10.2147/PGPM.S211259. PMID: 31564952. PMCID: PMC6732559.

19. Ortner M, Stange M, Schneider H, Schröder C, Buerger K, Müller C, Müller-Sarnowski F, Diehl-Schmid J, Förstl H, Grimmer T, Steimer W. 2020; Therapeutic drug monitoring of rivastigmine and donepezil under consideration of CYP2D6 genotype-dependent metabolism of donepezil. Drug Des Devel Ther. 14:3251–3262. DOI: 10.2147/DDDT.S247259. PMID: 32848364. PMCID: PMC7431170.

20. Zhong Y, Zheng X, Miao Y, Wan L, Yan H, Wang B. 2013; Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease. Am J Med Sci. 345:222–226. DOI: 10.1097/MAJ.0b013e318255a8f9. PMID: 22986607.

21. Xiao T, Jiao B, Zhang W, Tang B, Shen L. 2016; Effect of the CYP2D6 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease: a systematic review and meta-analysis. CNS Drugs. 30:899–907. DOI: 10.1007/s40263-016-0356-1. PMID: 27282366.

22. Gilani B, Cassagnol M. 2024. Biochemistry, cytochrome P450 [Internet]. StatPearls Publishing;Available from: https://www.ncbi.nlm.nih.gov/books/NBK557698/.